vincristine

P1/2, N=64, Suspended, National Cancer Institute (NCI) | Trial completion date: Dec 2026 --> Dec 2027 | Recruiting --> Suspended | Trial primary completion date: Feb 2026 --> Dec 2026

The most promising salvage options for patients responding insufficiently to treatment are the chemotherapy combinations, topotecan/vincristine/doxorubicin (TVD), topotecan/cyclophosphamide/etoposide (TCE), ifosfamide/carboplatin/etoposide (ICE) or topotecan/cyclophosphamide (TopoCy), or [131I]-mIBG therapy. Early-phase clinical trials are also a possible option in this setting.

The cytotoxicity and pro-apoptotic effects were significantly attenuated by the ROS scavenger NAC. These findings provide a solid preclinical foundation for the further development of this combination therapy and underscore the importance of the "computational prediction-mechanistic validation" strategy in advancing cancer drug discovery.

P1/2, N=50, Not yet recruiting, Novartis Pharmaceuticals

P3, N=406, Recruiting, University Hospital Heidelberg | Trial completion date: Mar 2031 --> Mar 2033 | Trial primary completion date: Mar 2031 --> Mar 2033

This study examined the effects of five anticancer agents-cisplatin, 5-fluorouracil, vincristine, irinotecan, and cyclophosphamide-on mouse skeletal muscle. Targeting ER stress may help prevent chemotherapy-induced muscle wasting. Further studies are needed to clarify mechanisms and develop protective strategies.

P2, N=30, Recruiting, University of Washington | Not yet recruiting --> Recruiting

Expression ratios of BAX/BCL-2, cleaved caspase-9/caspase-9, and cleaved caspase-3/caspase-3 notably increased. These findings suggest that FN enhances the efficacy of chemotherapy drugs by promoting intrinsic apoptotic pathways and may serve as a potential natural adjuvant in cancer therapy.

The patient achieved complete remission with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy and remains disease-free after three years. To our knowledge, this represents the first reported case of primary bilateral subconjunctival PTCL-NOS successfully managed with systemic chemotherapy, highlighting the importance of comprehensive evaluation and aggressive treatment in this unusual presentation.

By sharing the diagnosis and treatment process of this patient and reviewing the relevant literature, we aim to help clinicians enhance their understanding of two rare diseases, namely pleomorphic RMS and sarcomatoid carcinoma of the liver.

Vincristine, a cornerstone vinca alkaloid in pediatric oncology, has historically been regarded as a low-risk agent for drug-induced acute pancreatitis (DIAP). Vindesine may serve as a safe and effective alternative agent. These findings underscore the importance of updating pediatric chemotherapy safety guidelines for vinca alkaloid-containing regimens.

Berberine altered the microtubule cytoskeleton similarly to vincristine...Their relationship to berberine and its derivatives is novel. Berberine-type compounds may be new candidates against cancer; however, they may develop drug resistance.